AIDS
AIDS
5 years ago

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era
Prevot, Sophie, Casasnovas, Rene-Olivier, Delobel, Pierre, Recher, Christian, Goujard, Cécile, Bonnet, Fabrice, Algarte-Genin, Michele, Besson, Caroline, Mekerri, Nawel, Meyohas, Marie-Caroline, Lancar, Remi, Mounier, Nicolas, Delarue, Richard, Hendel-Chavez, Houria, Gabarre, Jean, Partisani, Marialuisa, Oberic, Lucie, Boue, François, the ANRS-CO16 LYMPHOVIR Cohort, Costello, Regis, Taoufik, Yassine, Coppo, Paul, Costagliola, Dominique, Dos Santos, Gabriella
Objective: Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival among patients with HIV-associated diffuse large B-cell lymphoma (DLBCL), the most frequent NHL subtype, has improved markedly in recent years. We aimed to analyze characteristics and outcomes of DLBCL in HIV-infected patients in the era of modern combined antiretroviral therapy (cART). Design: PLWHIV with lymphoma were prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015. We compared the patients treated with R-CHOP) (rituximab, cyclophosphamide, daunorubicin, vin-cristine, prednisolone) with HIV-negative DLBCL patients enrolled simultaneously in the R-CHOP arms of Lymphoma Study Association trials. Results: Among 110 PLWHIV with NHL, 52 (47%) had systemic DLBCL. These 52 cases had frequent extranodal disease (81%), poor performance status (35%) and advanced age-adjusted international prognostic index (aaIPI) (58%), and were mainly treated with R-CHOP (n = 44, 85%). Their median CD4+ T-cell count was 233 cells/μl, and 79% of patients were on cART. The 2-year overall and progression-free survival rates were both 75% (95% confidence interval: 64%, 88%). Factors associated with progression or death in univariate analysis were poor performance status [hazard ratio: 3.3 (1.2, 8.9)], more than one extranodal site [hazard ratio: 3.4 (1.1, 10.5)] and an advanced aaIPI [hazard ratio: 3.7 (1.0, 13.1)]. Progression-free survival after R-CHOP therapy did not differ from that of the HIV-negative counterparts (P = 0.11). Conclusion: In the recent cART era, despite frequent high-risk features, the 2-year overall survival of HIV-DLBCL patients reaches 75%. Outcomes after R-CHOP therapy are similar to those of HIV-negative patients with similar aaIPI.

Publisher URL: http://journals.lww.com/aidsonline/Fulltext/2017/11280/Outcomes_for_HIV_associated_diffuse_large_B_cell.7.aspx

DOI: 10.1097/QAD.0000000000001652

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.